Gaois

Similar terms:

This is a static copy of data that is exported from IATE on an occasional basis. It should not be assumed that information provided about an entry here will always correspond to the current version of the entry in IATE. That current version can be checked by clicking on the link on the upper right hand side of each entry. More information »

7 results

  1. INDUSTRY|chemistry · SOCIAL QUESTIONS|health|pharmaceutical industry

    #678923

    IATE #1330633
    eisíontas Reference "Rialachán (AE) 2022/1439 lena leasaítear Rialachán (AE) Uimh. 283/2013 a mhéid a bhaineann leis an bhfaisnéis a bheidh le cur isteach maidir le substaintí gníomhacha agus na ceanglais shonracha sonraí i ndáil le miocrorgánaigh, CELEX:32022R1439/GA Faomhadh an téarma seo mar chuid de Thionscadal Lex"
    ga
    impurity
    en
    Definition any unwanted chemical that is present in a manufactured product or that develops during formulation or upon ageing of that product Reference "COM-Terminology Coordination, based on: PharmTech.com. 'Evaluating Impurities in Drugs (Part III of III)' (17.2.2023)"
  2. SOCIAL QUESTIONS|health|pharmaceutical industry

    #682216

    IATE #3510060
    genotoxic impurity | DNA reactive impurity | mutagenic impurity
    en
    Definition impurity - for which there are test data or sufficient evidence - that has the potential to damage DNA at any level of exposure, with such damage possibly leading/contributing to tumour development Reference "COM-Terminology Coordination, based on:: EMEA. CHMP. 'Guideline on the limits of genotoxic impurities' (10.12.2024). London, 28 June 2006 CPMP/SWP/5199/02 EMEA/CHMP/QWP/251344/2006"
    Comment "This type of mutagenic carcinogen is usually detected in a bacterial reverse mutation (mutagenicity) assay. Other types of genotoxicants that are non-mutagenic typically have threshold mechanisms and usually do not pose carcinogenic risk in humans at the level ordinarily present as impurities. Therefore to limit a possible human cancer risk associated with the exposure to potentially mutagenic impurities, the bacterial mutagenicity assay is used to assess the mutagenic potential and the need for controls. Structure-based assessments are useful for predicting bacterial mutagenicity outcomes based upon the established knowledge."
  3. SOCIAL QUESTIONS|health|pharmaceutical industry

    #680004

    IATE #1554037
    próifíl eisíontais Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Context 'Is le foirmliú dáileoige béil soladach tobscaoilte nó le tuaslagán béil amháin a bhainfidh an t-athrú agus ní spreagfar athrú díobhálach ar phróifíl eisíontais cáilíochta ná ar phróifíl eisíontais cainníochta ná ar airíonna fisiciceimiceacha.' Reference "Rialachán Cur Chun Feidhme (AE) 2021/17 lena mbunaítear liosta modhnuithe nach n-éilíonn measúnú i gcomhréir le Rialachán (AE) 2019/6 ó Pharlaimint na hEorpa agus ón gComhairle, CELEX:32021R0017/GA"
    impurity profile
    en
    Definition "identity of impurities, quantity of impurities and source of impurities as well as description of unidentified impurities present" Reference "COM-Terminology Coordination, based on: - EMA. 'ICH Topic Q 3 B (R2) Impurities in New Drug Products' (17.2.2023). June 2006 CPMP/ICH/2738/99- PharmTech.com. 'Evaluating Impurities in Drugs (Part III of III)' (17.2.2023)"
    Comment Concerning pharmaceutical products, there are synthesis-related impurities, formulation-related impurities, dosage form-related impurities, method-related impurities, environmental-related impurities, impurities on aging, metabolite impurities.
  4. SOCIAL QUESTIONS|health|pharmaceutical industry

    #664636

    IATE #3592472
    eisíontas a bhaineann le próiseas Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    process-related impurity | process-related impurities
    en
    Definition impurity that is derived from the manufacturing process Reference "European Medicines Agency (EMA). 'ICH Topic Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Step 5. NOTE FOR GUIDANCE ON SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS (CPMP/ICH/365/96)' (21.1.2021)"
  5. SOCIAL QUESTIONS|health|pharmaceutical industry

    #664637

    IATE #3592473
    eisíontas a bhaineann le táirgí Reference "Rialachán Tarmligthe (AE) 2021/805 lena leasaítear Iarscríbhinn II a ghabhann le Rialachán (AE) 2019/6 ó Pharlaimint na hEorpa agus ón gComhairle, CELEX:32021R0805/GA ;Faomhadh an téarma seo mar chuid de Thionscadal Lex"
    ga
    product-related impurity
    en
    Definition molecular variant of the desired product (e.g. precursors, certain degradation products arising during manufacture and/or storage) which does not have properties comparable to those of the desired product with respect to activity, efficacy, and safety Reference "European Medicines Agency (EMA). 'ICH Topic Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Step 5. NOTE FOR GUIDANCE ON SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS (CPMP/ICH/365/96)' (21.1.2021)"
  6. AGRICULTURE, FORESTRY AND FISHERIES|means of agricultural production|means of agricultural production|plant health product

    #602093

    IATE #150111
    eisíontas ábhartha Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Context 'Sainaithníodh an t-eisíontas hiodraisín, ar ábhar tosaigh é, mar eisíontas ábhartha, le linn an mheasúnaithe, ós rud é gur aimsíodh é sna baisceanna plandaí píolótacha ar a ndearnadh athmheasúnú agus sna baisceanna plandaí ó na láithreáin tráchtála.' Reference "Rialachán Cur Chun Feidhme (AE) 2021/459 lena leasaítear Rialachán Cur Chun Feidhme (AE) Uimh. 540/2011 maidir le coinníollacha formheasa na substainte gníomhaí feinpiorasaimín, CELEX:32021R0459/GA"
    relevant impurity
    en
    Definition impurity that is particularly undesirable because of its toxicological, ecotoxicological or environmental properties Reference "COM-Terminology Coordination, based on: Regulation (EU) No 283/2013 setting out the data requirements for active substances, in accordance with Regulation (EC) No 1107/2009 concerning the placing of plant protection products on the market"
  7. SOCIAL QUESTIONS|health|pharmaceutical industry

    #690707

    IATE #3648708
    unqualifizierte Verunreinigung
    de
    Definition Verunreinigung, deren biologische Sicherheit unbekannt ist Reference COM-DE aufgrund der EN Definition
    unqualified impurity
    en
    Definition "impurity (substance that is not the active substance or an excipient in a medicinal product) whose biological safety is unknown" Reference "COM-Terminology Coordination and COM-EN, based on: EMA. ICH Topic Q 3 B (R2) Impurities in New Drug Products. Step 5. NOTE FOR GUIDANCE ON IMPURITIES IN NEW DRUG PRODUCTS (CPMP/ICH/2738/99) (9.12.2024), CPMP/ICH/2738/99, June 2006."
    Comment "An impurity can result from a chemical change in the active substance brought about during manufacture and/or storage of the new medicinal product by the effect of, for example, light, temperature, pH, water, or by reaction with an excipient and/or the immediate container closure system. In this case the impurity is a degradation product and its biological safety must also be known. The biological safety of metabolites of a medicinal product (which are also degradation products) must also be known and relevant data are normally included in safety and/or clinical studies."
    impureté non qualifiée
    fr
    Definition composant présent dans l'intermédiaire ou la substance active et qui n'est pas l’entité désirée, dont la sécurité biologique n’est pas connue Reference "COM-FR, d'après:Agence nationale de sécurité du médicament et des produits de santé (ANSM), Guide des bonnes pratiques de fabrication (19.12.2024), Glossaire, 2019"